New drug cocktail shows promise in shrinking HER2+ stomach tumors before surgery
NCT ID NCT05034887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests two approaches for HER2-positive stomach or gastroesophageal junction cancer that hasn't spread. One group gets trastuzumab deruxtecan alone before surgery. Another group gets a combination of trastuzumab deruxtecan, capecitabine, and durvalumab both before and after surgery. The main goal is to see how many patients have a major response in their tumor after treatment. The trial involves 64 adults aged 20 and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd), capecitabine, durvalumab
- What this could lead to
- If successful, this could point toward a more effective treatment approach for HER2-positive stomach cancer, potentially improving surgical outcomes and reducing recurrence.
- What could go wrong
- This is a small, early-phase trial (64 participants) without a comparison group, so results may not apply broadly. The drug combination also carries risks like lung inflammation or heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?